Open access peer-reviewed chapter

The Genetic Aspects of Behçet’s Disease: Role of Cytokine Genes Polymorphisms

Written By

Abdulrahman Al Asmari and Misbahul Arfin

Submitted: March 6th, 2019 Reviewed: July 27th, 2019 Published: October 2nd, 2019

DOI: 10.5772/intechopen.88856

Chapter metrics overview

710 Chapter Downloads

View Full Metrics


Behçet’s disease (BD) is a complex, multisystemic inflammatory disorder characterized by recurrent oral aphthous ulcers, ocular symptoms, skin lesions, and genital ulcerations. The etiology of BD is not yet clear though various factors including environmental, genetic and immunological ones have been implicated. Genetic predisposition is a major factor in disease susceptibility and multiple host genetic factors have been suggested to be involved in the development of BD. In addition to the positive association of HLAB*51, recent studies report additional independent associations in the non HLA loci. Single nucleotide polymorphisms (SNPs) in various genes including cytokines have been implicated in susceptibility to BD. However, the results are inconsistent and variation are found in several ethnic populations. Therefore, further genetic studies on BD patients of different ethnicity and genes associated with immunity are expected to elucidate BD pathogenesis and will contribute to the development of more targeted therapies and biomarkers.


  • Behçet’s disease
  • genetics
  • cytokines
  • TNF
  • interleukin
  • polymorphism

1. Introduction

Behçet’s disease (BD; MIM 109650) is a multisystemic inflammatory disorder characterized by recurrent oral aphthous ulcers, ocular symptoms, skin lesions, and genital ulcerations. BD has many features in common with systemic vasculitis. The prevalence of BD varies, it is more prevalent in the Far East, the Mediterranean and the Middle Eastern countries along the ancient Silk Road [1, 2, 3]. The highest prevalence has been reported in Turkey (80–420 cases per 100,000) followed by Israel (146.4), China (110), Iran (80), Korea (30.2), Japan (22), Saudi Arabia (20), Iraq (17), Morocco (15), and Egypt (7.5) cases per 100,000 [1, 3, 4].

Clinical and immunological understandings of the disease suggest that BD is a cornerstone between autoimmune and inflammatory disease [5]. Due to effectiveness of immunosuppressives [6] and involvement of human heat-shock protein 60 (HSP60) [7], it is considered as an autoimmune disease. While on the basis of lack of antigen-specific T-cells or significant high-titer auto-antibodies, insignificant involvement of histocompatibility complex (MHC) class I molecules together with unprovoked recurrent inflammation episodes mainly caused by neutrophils [8], the association of the M694V MEFV mutation with its susceptibility and the therapeutic effectiveness of colchicine, BD is classified as an auto-inflammatory disease [4].

Although it is thought that common environmental factors such as infections or exposures to toxins or to specific immunogens contribute to BD, development of disease is believed to occur only in genetically predisposed hosts. BD is a complex disease and different patients experience different symptoms. The etiology of BD is very complex and it is thought that environmental factors, genetic predisposition and immune dysregulation are involved in the pathogenesis of BD [9, 10, 11, 12, 13, 14]. The wide range of disease prevalence observed among different geographic locales is likely a result of differences in both environment and genetics. The aim of this study is to highlight the genetic aspect of BD with emphasis on the role of cytokine genes polymorphisms in the susceptibility/etiopathogenesis of BD.


2. Genetic aspect of Behçet’s disease

Genetic predisposition is a major factor in disease susceptibility and multiple host genetic factors have been suggested to be involved in the development of BD. The association of HLAB*51 with BD susceptibility has been confirmed in several populations since it was discovered more than four decades ago however, recent studies indicate association in the major histocompatibility complex class I region and several non HLA loci also. Class I alleles, HLA-A*26, -B*15, -B*27, and -B*57, have been reported as independent risk factors for Behçet’s disease while HLA- A*03 and -B*49 are protective for it [15].

The candidate gene approach has been useful in identifying susceptibility and severity genes in BD. Single nucleotide polymorphisms (SNPs) in various genes (IL-10, TNF-α, TNF-β, STAT4, IL23R, CD40, CCR1/CCR3, STAT3, MCP-1, TGFBR3, FCRL3, SUMO4, UBAC2) have been implicated in susceptibility to BD. However, the results are inconsistent and variation are found in several ethnic populations. Genome-wide association studies have also identified associations with IL23R–IL12RB2, IL10, STAT4, CCR1-CCR3, KLRC4, ERAP1, TNFAIP3, and FUT2 loci [15]. Moreover rare mutations in IL23R, TLR4, NOD2, and MEFVr genes have been found to be linked with BD pathogenesis by targeted next-generation sequencing.

The variations in the mRNA expression/gene function indicate the role of the risk alleles in the pathogenesis of disease. Several susceptibility genes, which may regulate the immune reaction, have been found to be associated with BD. However, the precise mechanism of these genes in the development of BD is currently unknown [10, 11, 16]. The genes identified are involved in both innate and adaptive immunity and support the idea that polarization in Th1/Th17 pathway plays a critical role in BD pathogenesis. Commonalities of susceptibility genes with other immune-related diseases/inflammatory disorders shows shared features of immune related diseases with BD. The interaction between genetic factors and environmental factors has also been suggested in several recent studies.

Cytokines are believed to mediate inflammation in BD [17, 18]. Various studies have found increased levels of tumor necrosis factor (TNF)-α and decreased levels of interleukin (IL)-10 in the serum and active lesions of BD patients and suggested that these cytokines play a significant role in the immune response, pathogenesis and activity in BD [12, 19, 20, 21, 22, 23, 24].

Cytokines play critical roles in the pathogenesis of BD, since they mediate many of the effector and regulatory functions of immune and inflammatory responses [14, 17]. Genetic polymorphisms in several cytokine genes have been described and demonstrated to influence gene transcription, leading to inter individual variations in cytokine production. It has been suggested that genetic polymorphisms that regulate the production of certain cytokines are important determinants of susceptibility to BD and its some of the clinical and laboratory features [14, 25, 26]. BD has been considered to be a typical Th1-mediated inflammatory disease, characterized by elevated levels of Th1 cytokines such as IFN-γ, IL-2, and TNF-α. Recently it has been reported that Th1- and Th17-related cytokines and signaling molecules participated in BD pathogenesis [27, 28].

A number of studies reported that the levels of T helper Type 1 cytokines are increased in sera of the patients with BD. Some studies have shown that the maximal capacity of cytokine production varies among individuals and correlate with single nucleotide polymorphism in various cytokine genes [29, 30, 31, 32]. However the results of the association of cytokines genes polymorphism with susceptibility and pathogenesis of BD are inconsistent and further studies involving different ethnic populations have been suggested [14].


3. Tumor necrosis factor (TNF)-α polymorphisms

Besides HLA-B51 molecules, SNPs in TNF genes have been implicated in susceptibility to BD [14, 33, 34, 35, 36, 37]. TNF-α is a pro-inflammatory cytokine and involved in regulation of the immune response. It is encoded in the Class III region of the HLA complex adjacent to HLA-B. TNF-α mediates the activation of macrophages and apoptosis and it is involved in recurrent inflammatory episodes in BD patients [23, 38]. Many studies have suggested it as both positional and functional candidate gene in the onset and progression of BD [14, 33, 34, 35, 39].

Promoter polymorphism of TNF-α (−308G/A) and intronic polymorphism TNF-β (252A/G) have been associated with variations in the level of circulating TNF-α [40]. TNF-α (−308G/A) polymorphism (rs1800629) results into a less common allele-A (allele 2) which leads to increased TNF-α production in vitro [41] and higher rate of TNF-α transcription than wild type allele-G (allele 1). Allele-A produces 6–7 fold higher levels of TNF-α transcription [42, 43, 44]. TNF-α production and expression is regulated by single nucleotide polymorphisms (SNPs) in TNF-α gene [25, 42]. Several SNPs in TNF-α gene have been associated BD in different ethnic groups [14, 36, 45, 46, 47]. The outcome of various studies on association between BD and SNPs of TNF-α in different ethnic groups are summarized in Tables 16.

Korean94/94GA polymorphismNo association[49]
Korean115/114GA polymorphismNo association[50]
Turkish99/96GA polymorphismNo association[52]
Turkish107/102GA polymorphismNo association[38]
Turkish97/127GA polymorphismNo association[53]
Turkish102/102GA polymorphismNo association[45]
Lebanese48/90GA polymorphismNo association[51]
Iranian147/137GA polymorphismNo association[48]
Iranian (Azeri Turkish)53/79GA polymorphismNo association[54]
Moroccan120/112GA polymorphismNo association[47]
Tunisian89/157GA polymorphismNo association[46]
Caucasoid133/354GA polymorphismNo association[39]
Meta-analysisGA polymorphismNo association[36]
Meta-analysis1372/1754GA polymorphismSusceptible[34]

Table 1.

Association of TNF-α-308 polymorphism with BD susceptibility.


Turkish107/102A/G polymorphismNo association[38]
Turkish30/20A/G polymorphismNo association[56]
Korean254/344A/G polymorphismNo association[33]
Korean115/114A/G polymorphismNo association[50]
German92/51A/G polymorphismNo association[56]
Lebanese48/90A/G polymorphismNo association[51]
Moroccan120/112A/G polymorphismNo association[47]
Iranian (Azeri Turkish)64/101A/G polymorphismNo association[57]

Table 2.

Association of TNF-α –238 polymorphism with BD susceptibility.


Turkish99/103C/T polymorphismSusceptible[29]
Iranian (Azeri Turkish)53/79C-alleleSusceptible[54]
Korean254/344C/T polymorphismSusceptible[33]
Korean115/114C/T polymorphismNo association[50]
Lebanese48/90C/T polymorphismNo association[51]
Caucasoid (UK)133/354C/T polymorphismSusceptible[39]
Meta-analysisC- alleleSusceptible[36]
Caucasian*738/964C- alleleSusceptible[35]

Table 3.

Association of TNF-α –1031 polymorphism with BD susceptibility.


Korean115/114T/C polymorphismNo association[50]
Lebanese48/90T/C polymorphismNo association[51]
Moroccan120/112T/C polymorphismNo association[47]
Iranian (Azeri Turkish)64/101C-alleleSusceptible[57]

Table 4.

Association of TNF-α –857 polymorphism and BD in various populations.


Korean254/344A/C polymorphismSusceptible[33]
Korean115/114A/C polymorphismNo association[50]
Moroccan120/112A/C polymorphismNo association[47]
Lebanese48/90A/C polymorphismNo association[51]
Meta-analysisA/C polymorphismNo association[36]
Asian*486/560A/C polymorphismNo association[35]

Table 5.

Association of TNF-α–863 polymorphism with BD in various populations.


Turkish99/96A/G polymorphismNo association[52]
Turkish107/102A/G polymorphismNo association[38]
Moroccan120/112A/G polymorphismNo association[47]

Table 6.

Association of TNF-α–376 polymorphism with BD susceptibility.

3.1 TNF-α (−308 G/A) polymorphism

A number of studies has determined the relationship between the -308A/G polymorphism and BD with inconsistent results (Table 1). The genotype GA and allele-A are associated with susceptibility of BD in Saudis [14] while genotype GG and allele G are associated with its susceptibility in Korean patients [33]. On the other hand no association is found in Caucasoid [39], Iranian [48], Iranian (Azeri Turkish) [54], Korean [49, 50] Lebanese [51], Tunisian [46], Turkish [38, 45, 52, 53] and Moroccan [47].

Two independent meta-analysis have revealed an association between −308A and BD risk in the overall [34, 35] however, stratification by ethnicity indicates that the −308A allele is significantly associated with BD risk in the Asian population [35].

3.2 TNF-α (−238 A/G) polymorphism

The TNF-238A/G polymorphism has been studied in BD patients from different ethical populations and several reports are available on the association between the TNF−238A/G polymorphism and BD risk with contrast results. Genotype AA is found to be associated with BD in Turkish population [55] whereas genotype GG is associated with BD in Iranian patients [48]. Other individual studies on German [56], Iranian (Azeri Turkish) [57], Korean [33, 50], Lebanese [51], Moroccan [47] and Turkish [38, 56] BD patients show no association of TNF−238A/G polymorphism with susceptibility of BD (Table 2). However two meta-analysis indicates that allele-A is associated with BD susceptibility [35, 36]. In the subgroup analysis by ethnicity, Zhang et al. [35] suggests that the BD cases has a significant higher frequency of A in the Caucasian than that in the controls.

3.3 TNF-α (−1031 C/T) polymorphism

There is a strong evidence indicating the role of TNF-α (−1031 C/T) Polymorphism with BD susceptibility. A number of studies examined the association of TNF-α −1031C/T with BD in different populations. Results indicate, a significant association between the TNF-α −1031C/T polymorphism and BD susceptibility in Turkish [29, 58], Iranian (Azeri Turkish) [54], Korean [33], and Tunisian patients [46] (Table 3). Touma et al. [36] in a meta-analysis, identified a significant associations between the −1031C/T polymorphisms and BD risk. Stratifying by ethnicity, in another meta-analysis a significant association in the Caucasian population is noticed [35]. Radouane et al. [47] suggested that TNF-1031C constitutes a susceptibility allele for BD in Moroccan, especially with genital ulcers.

In contrast, Chang et al. [50] discovered no significant difference in the allele frequency of TNF-α −1031C/T between patients with BD and controls in a Korean population. There was no significant association of this polymorphism in Lebanese BD patients also [51]. Moreover the analysis of the influences this polymorphism on various clinical manifestations of BD showed that TNF-α −1031C is not related to the presence of clinical features, such as oral and genital ulceration and uveitis.

3.4 TNF-α (−857 T/C) polymorphism

A number of studies has been focused on the association between the TNF-α-857T/C polymorphism and BD risk (Table 4). Two independent studies indicate an association of TNF-α-857T/C polymorphism with BD susceptibility in Korean and Iranian (Azeri Turkish) Cohort [33, 57]. Other studies performed on Korean, Lebanese, and Moroccan BD patients show no significant association of this polymorphism and BD susceptibility [47, 50, 51]. However a meta-analysis suggested that T-allele of TNF-α-857T/C polymorphism is associated with BD susceptibility [36]. Later on another meta-analysis also indicated that this association is a significant risk factor in Asian population [35].

3.5 TNF-α (−863 A/C) polymorphism

TNF-863A/C polymorphisms has been studied in Korean, Moroccan and Lebanese BD patients. Results of these studies indicated that there is no significant association of polymorphism with BD susceptibility (Table 5) [47, 50, 51] though one study suggested an association in Korean patients [33]. However two independent meta-analysis also did not find any significant role of this polymorphism in BD susceptibility [35, 36].

3.6 TNF-α (−376 A/G) polymorphism

Three reports are available on −376A/G polymorphism in BD, two studies were performed in Turkish while the third one in Moroccan patients. These studies identified no significant association with BD risk (Table 6). The results of the meta-analysis by Zhang et al. [35] also showed that the TNF-376A/G polymorphism is not associated with BD susceptibility and this polymorphism does not appear to have a significant association with overall BD risk.


4. TNF-β (–252A/G) polymorphism

TNF-β has been reported to contribute to the susceptibility of some inflammatory and autoimmune diseases [58, 59, 60, 61, 62]. Gamma delta T cells of BD patients produce higher levels of TNF-β than those of healthy controls [63, 64]. A polymorphism in the intron 1 of TNF-β has been associated with higher TNF-α and TNF-β production. TNF-β (+252A/G) polymorphism (rs909253) contains a Guanine (G) on one allele and an adenine (A) on the alternate allele. TNF-β +252G allele is defined as mutant allele and known as TNF-β*1 (allele-1). This mutant allele-1 is associated with increased levels of TNF-α and TNF-β [65, 66].

To the best of our knowledge five studies have been focused on TNF-β (+252A/G) polymorphism and BD (Table 7). The results of three studies in Saudi, Korean and Tunisian BD patients indicated that TNF-β (+252A/G) polymorphism has no significant association with BD susceptibility. However one report from Palestinian and Jordanian populations indicates that the frequency TNF-β +252 A allele (allele-2) is increased in BD cases compared to controls [67]. On the basis of strong linkage disequilibrium found between HLA-B*51 and allele-A of TNF-β (+252A/G) polymorphism it has also been suggested that that both the alleles contribute to BD risk and their co-expression may cause severe eye pathogenicity leading to blindness [67]. Another report by Mizuki et al. [68] shows that the frequency of homozygous genotype (GG) of TNF-β (+252A/G) is significantly decreased in Japanese ocular BD patients than controls.

Saudi61/211AG polymorphismNo association[14]
Tunisian89/157AG polymorphismNo association[46]
Korean94/94AG polymorphismNo association[49]
Middle eastern102/115A-alleleSusceptible[67]

Table 7.

Association of TNF-β–252 polymorphism with BD susceptibility.


5. Interleukin (IL) gene polymorphisms

Interleukins are cytokines that mediate communication between cells. Interleukins regulate cell growth, differentiation, and motility. They are particularly important in stimulating immune response, such as inflammation. ILs (IL-1 to IL-38) function and play significant role in various diseases and their expression/production is influenced by the polymorphisms and mutations in their encoding genes [69].

5.1 IL-10 gene polymorphism

IL10 gene encodes IL-10 cytokine which suppresses the production of proinflammatory cytokines such as IL-1, IL-6, IL-12, TNF, and interferon gamma (IFN-γ), and inhibits the costimulatory activity of macrophages for T cell and NK cell activation [70]. IL-10 production may be regulated at the transcriptional level and several single nucleotide polymorphisms (SNPs) at the promoter region of IL-10 gene have been shown to be associated with changes in the expression levels of IL-10 [25, 42].

Numerous recent studies have demonstrated an association between BD and SNPs of IL10. Three polymorphisms -1082 A/G (rs1800896), -819 T/C (rs1800871) and -592 A/C (rs1800872) in the promoter region of the IL-10 gene are correlated to the expression level of IL-10. There are inconsistent reports on the association of IL-10-1082 A/G, -819 T/C and -592 A/C polymorphisms and BD (Tables 810). Two recent studies suggested significant association of genotype GG of IL-10-1082 A/G with BD susceptibility in Saudis [14] and Egyptian [71]. Earlier Wallace et al. [72] showed weak association of genotype AA with BD in UK and middle-eastern cohort. Moreover a meta-analysis also shows that there is a significant association of IL-10-1082 A/G polymorphism with BD susceptibility [34]. While there is no significant association of this polymorphism in Turkish and Iranian BD patients (Table 8) [28, 45, 53].

UK+ME178/295AAWeekly associated[72]
Turkish97/127GA polymorphismNo association[53]
Turkish102/102GA polymorphismNo association[45]
Iranian150/140GA polymorphismNo association[28]

Table 8.

Association of IL-10-1082 polymorphism with BD susceptibility.

Chinese407/679CT polymorphismSusceptible[74]
Chinese Han718/1753T-alleleSusceptible[75]
Turkish102/102CT polymorphismNo association[45]
Turkish97/127CT polymorphismNo association[53]
Turkish1215/1279CT polymorphismNo association[11]
Japanese611/737CT polymorphismNo association[11]
Korean119/140CT polymorphismNo association[11]
Iranian150/140CT polymorphismNo association[28]
Overall mixed1945/2156CT polymorphismSusceptible[11]
Meta-analysis2472/2820CT polymorphismSusceptible[34]

Table 9.

Association of IL-10-819 polymorphism with BD susceptibility.

Iranian150/140CA polymorphismNo association[28]
Iranian (Azeri Turkish)47/58A-AlleleSusceptible[76]
Chinese Han718/1753A-AlleleSusceptible[75]
Turkish102/102CA polymorphismNo association[45]
Turkish97/127CA polymorphismNo association[53]
Turkish1215/1279CA polymorphismNo association[11]
Japanese611/737CA polymorphismNo association[11]
Korean119/140CA polymorphismNo association[11]
Overall mixed1945/2156CA polymorphismSusceptible[11]
Meta-analysis2294/2525CA polymorphismSusceptible[34]

Table 10.

Association of IL-10-592 polymorphism with BD susceptibility.

IL-10-819 T/C polymorphism has been studied in different populations (Table 9). Reports indicate that IL-10-819 T/C polymorphism is associated with susceptibility of BD in Algerians [73], British [72], Chinese [74, 75] and Saudi patients [14]. While it is not significantly associated with BD in Turkish [11, 45, 53], Iranian [28], Japanese and Korean patients [11]. However two independent meta-analysis showed that IL-10-819 T/C polymorphism is associated with BD [11, 34]. In a meta-analysis containing of 2472 cases and 2820 controls, Liang et al. [34] suggested that IL-10-819 T/C polymorphism is associated with BD susceptibility.

Available literature shows that 11 studies focused on relationship of IL-10-592 A/C polymorphism and BD risk (Table 10). A significant association of this polymorphism has been reported in five studies from different ethnicity namely Algerian [73], Iranian (Azeri Turkish) [76], Chinese Han [75], Saudi [14] and Spanish BD patients [77]. In our study with Saudi patients we found that −592 AA genotypes of IL-10 is significantly associated with susceptibility risk of BD in Saudi patients [14].

On the other hand three studies on Turkish [11, 45, 53], one each on Iranian [28], Japanese and Korean BD patients [11] show no significant association of this polymorphism with BD susceptibility. A meta-analysis containing 2294 patients and 2525 controls suggested that IL-10-592 A/C polymorphism is associated with BD susceptibility [34].

Two independent GWA studies of Turkish and Japanese populations show that IL-10 is among the first two BD susceptibility loci outside the MHC with genome-wide significance [11, 16]. Intronic polymorphism (rs1518111) is associated with BD susceptibility in the Turkish population [16] while promoter polymorphisms in IL-10 gene (rs1800871 and rs1800872) are associated with BD in Japanese [11]. The variant rs1518111 has been replicated in BD patients of British, Greek, Korean and Middle Eastern ethnicity and rs1800872 replicated in Turkish and Korean samples [11, 16]. Recently Wu et al. [74] reported the replication of rs1518111 and rs1800871 variants in BD patients from Han Chinese population. The SNP rs1518111 has also been replicated in in the Iranian population showing association with BD [78]. The data from HapMap Project indicate that these three polymorphisms are in strong linkage disequilibrium in populations from both European and Asian ancestries. The decrease in risk allele A of rs1518111 is associated with decreased IL10 expression in monocytes by 35% compared with the non-risk allele G in Turkish patients with BD.

The homozygous genotype AA of rs1518111 is associated with decrease in IL-10 protein in monocytes and found to be stimulated with Toll-like-receptor ligands, such as lipopolysaccharide or the lipoprotein Pam3Cys and muramyl dipeptide [16]. Talat et al. [71] reported that IL-10 serum levels are lower in BD patients than in controls. Baris et al. [79] suggested that IL-10 polymorphisms can be statistically associated with the disease symptoms and used as prognostic factors.

5.2 IL-1 gene polymorphism

Several cytokine genes may play crucial roles in host susceptibility to Behçet's disease (BD), since the cytokine production capacity varies among individuals and depends on the cytokine gene polymorphisms. Interleukin-1 (IL-1) and the IL-1 receptor (IL-1R) family plays an important role in the pathogenesis of inflammatory diseases. The association of the IL-1 cluster gene polymorphisms with the development of BD has been investigated in several studies.

5.2.1 IL-1α −889C/T polymorphism

Six reports are available on IL-1α -889C/T polymorphism and Behçet’s disease (Table 11). Out these five studies were performed on Turkish patients [55, 58, 80, 81, 82] while one on Iranian BD patients [48]. There was no association of this gene polymorphism and the susceptibility of BD except one study which showed CC genotype to be associated with BD susceptibility in Turkish patients [55].

Turkish132/106IL-1α-889C/TNo association[80]
Turkish72/163IL-1α-889C/TNo association[81]
Turkish80/105IL-1α-889C/TCC associated[55]
Turkish57/57IL-1α-889C/TNo association[58]
Turkish97/77IL-1α-889C/TNo association[82]
Iranian150/140IL-1α-889C/TNo association[48]
Turkish132/106IL-1β-511C/TNo association[80]
Turkish80/105IL-1β-511C/TCC associated[55]
Turkish57/57IL-1β-511C/TNo association[58]
Turkish97/77IL-1β-511C/TNo association[82]
Turkish57/57IL-1β-3962C/TNo association[58]
Turkish80/105IL-1β-3962C/TCC associated[55]
Turkish97/77IL-1β-3962C/TNo association[82]
Iranian150/140IL-1β-3962C/TNo association[48]

Table 11.

Association of IL-1 polymorphisms with BD susceptibility.

5.2.2 IL-1β −511C/T polymorphism

Four studies are found which focused to assess the importance of IL-1β −511C/T polymorphism for BD susceptibility (Table 11). The comparisons of allele and genotype failed to detect any statistical association under the random effect model in three studies [58, 80, 82] however one study reported that CC genotype of IL-1β −511C/T polymorphism is associated with BD susceptibility in Turkish patients [55].

5.2.3 IL-1β −3962 C/A polymorphism

Some workers have studied IL-1 β −3962 C/A polymorphism and assessed the effect of the IL-1β −3962C/A polymorphism in the occurrence of BD in Turkish and Iranian patients (Table 11). They did not find any significant association between IL-1β −3962 C/A polymorphism with BD between allele and genotype frequencies in Turkish and Iranian BD patients [48, 58, 82] however one study indicates association of IL-1 β −3962 C/A polymorphism with BD in Turkish patients [55].

Ozçimen et al. [82] studied IL-1 cluster gene polymorphisms in Turkish patients with Behçet's disease and suggested that polymorphisms in IL-1β gene may affect host susceptibility to BD. The IL-1β production in the active period has been found to be greater than in the remission period of BD. IL-1β production is considered to be related to posterior segment type attacks of Behçet's disease [83].

Baris et al. [79] observed no significant differences between the groups with respect to the IL-1Ra, IL-1β, IL-2, IL-6 and the IL-10 gene polymorphism distributions and suggested that the IL-1RN2 gene polymorphism is correlated with the presence of articular involvement and the IL-1β gene polymorphism with the presence of an ocular lesion. On the basis of the correlations between the articular involvement and IL-1RN, the ocular involvement and the IL-1β, gene polymorphisms, it has been suggested that these polymorphisms could be statistically associated with the disease symptoms and may be used as prognostic factors [79].


6. Interleukin (IL)-6

IL-6 pleitropic cytokine is involved in immune and inflammatory responses. Various polymorphisms in IL-6 gene have been associated with chronic inflammatory and autoimmune disorders [84, 85, 86, 87, 88]. Higher levels of IL-6 and increased expression of IL-6 mRNA have been reported in subjects with active BD [20, 89, 90]. A few studies have focused on the polymorphism of IL-6 −174 G/C in BD patients (Table 12). The polymorphism of IL6 −174 G/C does not modulate clinical expression of BD. The single nucleotide polymorphism of the IL-6 does not appear to be associated with BD susceptibility in Egyptian [71], Korean [90], Tunisian [20], Turkish and German patients [53, 56]. The GG genotype of IL-6 −174 G/C polymorphism is protective in Iranian population [48]. It is believed that the scarcity of studies of polymorphism of IL-6 in BD is related to the fact that IL-6 is a pro-inflammatory cytokine of Th2, whereas BD is a Th1 disease. Recently a meta-analysis suggested that IL-6-174 G/C polymorphism decreases the risk of BD [91].

Tunisian43/43G/C polymorphismNo association[20]
Egyptian87/97G/C polymorphismNo association[71]
Turkish/German121/70G/C polymorphismNo association[56]
Turkish97/127G/C polymorphismNo association[53]
Korean89/123G/C polymorphismNo association[90]
Meta-analysis2065/1159G/C polymorphismDecrease the risk[91]

Table 12.

Association of IL-6 (174G/C) polymorphism with BD susceptibility.


7. IL23R-IL12RB2 polymorphisms

The IL23R–IL12RB2 polymorphisms in Behçet’s disease have been subject of several studies in various ethnic populations (Table 13). The IL23R–IL12RB2 locus is one of the few loci with genome-wide significance. The SNP rs1495965, located in the intergenic region between IL23R and IL12RB2 is associated with BD in Japanese [11]. Another polymorphism (rs924080) in the intergenic region between IL23R and IL12RB2 has been associated with BD in Turkish patients [16]. However, these association are not replicated in Korean, Middle Eastern Arab, Greek, and British subjects possibly due to small sample size [16].

Chinese Han407/421rs924080
Chinese Han1206/2475rs3024490
Chinese Han806/1600rs3212227Susceptible[96]
Chinese Han27/32rs17375018Susceptible[97]
decrease risk[73]

Table 13.

Association of IL23R-IL12RB2 polymorphisms with BD susceptibility.

The rs924080 has been replicated in the Iranian population and major allele is associated with BD [78]. Other polymorphisms rs7539328, rs12119179, rs1495965 have also been associated with BD susceptibility in Iranian patients [92]. Moreover minor allele of IL23R polymorphisms, Arg381Gln in the Turkish population and Gly149Arg in the Japanese population are associated with protection from BD as these variants reduce its ability to respond to IL-23 stimulation [99]. Disease–associated, intergenic non-coding variants (major alleles) are associated with increased expression of IL23R compared with the disease-protective minor alleles [99].

The IL-23 receptor is expressed on the surface of Th17 cells and macrophages. It is encoded by IL23R gene. IL-23 is composed of p19 and p40 subunits which is shared with IL-12. IL-23, being a proinflammatory cytokine promotes Th17 cell development and induces the production of IL-1, IL-6, IL-17 and TNF [100]. Th17 cells by producing IL-17 play a significant role in inflammation and autoimmune diseases. Steinman [101] suggested that the disease-associated alleles increase IL-23 receptor expression or signaling compared with the disease-protective alleles. Thus it is evident that the disease-associated variants increase the BD susceptibility by influencing IL23R, however an alternative or additional role to influence expression of the other nearby gene, like IL12RB2, cannot be excluded. IL-12 receptor beta2, a subunit of IL-12 receptor is encoded by IL12RB2 gene. IL12RB2 is responsible for high-affinity IL-12 binding and IL-12 dependent signaling, and plays an important role in Th1 cell differentiation. IL-12 has been suggested to be involved in Th1 responses, T cell and NK cell cytotoxicity, and IFN-γ production by T cells and NK cells [102]. As there is no data available on quantitative trait loci for these non-coding variants influencing IL12RB2 or IL23R expression, there is a possibility that their effects are expressed only in a specific cell type or under certain conditions as suggested by Takeuchi et al [15].

Yu et al. [95] performed genome wide association study on 1206 patients with BD and 2475 healthy controls and confirmed the association of IL-10 819 C/T and IL23R IL12RB2/rs924080 with BD. They (loc. cit.) also identified two susceptibility single nucleotide polymorphisms in IL10 and IL23R-IL12RB2 (rs3024490 and rs12141431) with BD in Han Chinese.


8. IL12A polymorphisms

IL12A encodes IL-12p35, a subunit of the heterodimer of IL-12, is known to play a critical role in polarization of the Th1 pathway through differentiation from naïve CD4+ T cells. A variant rs1780546, located in the intergenic region near IL12A has been associated with BD in a Turkish cohort however the association did not achieve genome-wide significance as it is not polymorphic in the Japanese cohort [99]. Recently, Kappen et al. [103] reported an association of rs1780546 with BD susceptibility and showed genome-wide association after meta-analysis with previous Turkish GWAS data. This GWAS was based on 336 cases and 5843 controls in cohorts of mixed ethnicity using linear mixed models to correct for ancestry differences and family structure and/or cryptic relationships. However no report is available on functional aspect of rs1780546 [102].


9. IL-33 gene polymorphism

Members of the IL-1 family play a pivotal role in the inflammatory responses [104]. IL-33 belongs to IL-1 superfamily. Some studies have implicated the IL-33 ligand for the ST2 receptor in the pathogenesis of BD [105, 106, 107]. IL-33 is encoded by IL-33 gene and expressed in epithelial, endothelial, inflammatory and central nervous system cells. IL-33 can function both as a cytokine and as a nuclear factor regulating gene transcription due to the fact that its expression increases in pro-inflammatory conditions. Cells of the affected area play a significant role in the pathogenesis of BD by recruiting, activating and promoting survival of inflammatory cells. Therefore the use of immunosuppressant like azathioprine, cyclosporine, corticosteroids or anti-TNF-α monoclonal antibodies (mAb) which interferes the cytokine network is the basis of BD treatment strategies [6, 20, 108].

The TT variants of rs7044343 and rs11792633 polymorphisms in IL-33 gene are very rare, and the T allele frequencies of these polymorphisms has been reported to be lower in the BD group compared to the controls. The rs7044343 and rs11792633 variants of IL-33 gene are associated with the decreased risk of BD in Turkish cohort. It has been suggested that IL-33 acts a protective role on the pathogenesis of BD [109].


10. Interferon-γ (IFN-γ)

IFN-γ is antiviral, antitumor and immunomodulatory cytokine. It has a critical role in modulating the IL-4, IL-10 and IL-12 cytokine network pathway. It is also considered as a pro-inflammatory cytokine because of its effects on TNF activity. It has been reported that the frequencies of IFN-γ +874A allele and A/A genotype are higher in BD patients than in healthy controls, and individuals with this genotype are more susceptible to the disease [55]. However later studies on Turkish and Iranian patients failed to find any significant association of IFN-γ +874 A/T polymorphism with BD susceptibility (Table 14) [28, 53].

Turkish97/127A/T polymorphismNo association[53]
Iranian150/140A/T polymorphismNo association[28]

Table 14.

Association of IFN-γ (+874A/T) polymorphism with BD susceptibility.

11. Transforming growth factor-β1 gene polymorphism

Transforming growth factor-β1 (TGF-β1) is an effective immunosuppressive cytokine. It is produced in response to tissue injury by activated macrophages. TGF-β1 is responsible for inhibition of macrophage activation and modulation of T cell function [110, 111]. It is also involved in tissue fibrosis by increasing the synthesis of extracellular matrix components [112]. The frequency of TGF-β1 codon 10–25 T/C-G/C genotype in Turkish BD patients has been reported to be higher than those of healthy controls [53] while GG genotype has been reported to be susceptible to BD in Iranian cohort (Table 15) [28].


Table 15.

Association of TGF-β1 (509 C/T) polymorphism with BD susceptibility.

Recent studies have focused on the functional relevance of the various genes associated with susceptibility of BD and possible interaction between the genes located within and outside the MHC region [14, 24, 113, 114]. The functional relevance of allele A and genotype GA of TNF-α (308G/A) and association with BD has been indicated in various studies [24, 114]. The increased frequency of allele-A in BD patients is linked with higher levels of TNF-α reported in active BD patients as compared to controls [24, 114].

The pro-inflammatory cytokines induce inflammation and the severity of the inflammatory responses is influenced by the levels of cytokines. The activated macrophages produce higher levels of cytokines affecting not only the severity of the local inflammatory responses but also exert systemic effects. The over-expression of these cytokines is considered to be responsible for the pathogenesis of recurrent BD [33]. TNF-α, a pro-inflammatory cytokine has been suggested to be responsible for the pathogenesis of BD by activating T-cells and neutrophils [115].

On the other hand increased frequency of low producer 1082GG genotype of IL-10 (an anti-inflammatory cytokine) in BD patients may not suppress the TNF-α- activity and resulting inflammatory responses, as IL-10 is known to limit the secretion of pro-inflammatory cytokines, such as TNF-α and IL-12 [70]. Moreover the deficiency of IL-10 and resulting prolonged activation of mononuclear cells may lead to an augmented efflux of inflammatory cytokines and further aggravate the severity of BD as IL-10 is a multi-functional cytokine with role in diverse areas of the human immune system [116].

The information regarding the association of various gene polymorphisms will have prognostic value for future clinical observations. Especially the data of TNF-α (−308) polymorphism will provide guideline in anti-TNF-α therapy as patients with GG genotype are better responders to anti-TNF-α treatment than those with AA or GA [117, 118]. However, such genetic associations with BD susceptibility need further validation and investigation in more patients with BD from various ethnic populations, as they may have implications for the development of novel therapies as suggested by Xavier et al [78].

12. Conclusion

In spite of recent advances in genetics and immunology leading to a better understanding of the immunopathogenesis, the etiology of BD is still unclear. Various genetic, immunological and micro- and macro-environmental factors are believed to be involved in the development of BD. The HLA-B∗51 allele and variants in IL-10, TNF-α, TGF-β and at the IL-23–IL-12RB2 loci are the genetic factors most closely associated with BD. The variations in the association between various polymorphisms discussed and BD in different ethnicity/populations may reflect the heterogeneity in the genetic susceptibility to this disorder. Since the clear pathogenesis of BD remains to be elucidated, it is highly suggestive that multiple host genetic factors are involved in the development of BD. Therefore, further genetic studies on BD patients of different ethnicity and genes associated with immunity are expected to elucidate BD pathogenesis and also to contribute to the development of more targeted therapies and biomarkers.


Authors wish to thank MSD administration for facilities and support.

Conflict of interest

No conflicts of interests.


  1. 1. Yurdakul S, Yazici Y. Epidemiology of Behçet’s syndrome and regional differences in disease expression. In: Yazici Y, Yazici H, editors. Behçet’s Syndrome. 1st ed. New York: Springer; 2010. pp. 35-52
  2. 2. Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Behcet’s disease with emphasis on the role of immunological aberrations. Clinical Rheumatology. 2010;29:1211-1216. DOI: 10.1007/s10067-010-1491-6
  3. 3. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, et al. Behçet’s disease in Iran: Analysis of 6500 cases. International Journal of Rheumatic Diseases. 2010;13:367-373. DOI: 10.1111/j.1756-185X.2010.01549.x
  4. 4. Cho S, Cho S, Bang D. New insights in the clinical understanding of Behcet’s disease. Yonsei Medical Journal. 2012;53:35-42. DOI: 10.3349/ymj.2012.53.1.35
  5. 5. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmunity Reviews. 2012;11(10):687-698. DOI: 10.1016/j.autrev. 2011. 11.026
  6. 6. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Survey of Ophthalmology. 2005;50:297-350. DOI: 10.1016/j.survophthal.2005.04.009
  7. 7. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behcet’s disease. Clinical and Experimental Rheumatology. 2003;21:S44-S48
  8. 8. Stojanov S, Kastner D. Familial autoinflammatory diseases: Genetics, pathogenesis and treatment. Current Opinion in Rheumatology. 2005;17:586-599
  9. 9. Chi W, Zhu X, Yang P, Liu X, Lin X, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Investigative Ophthalmology & Visual Science. 2008;49(7):3058-3064. DOI: 10.1167/iovs. 07-1390
  10. 10. Jiang Z, Yang P, Hou S, Du L, Xie L, Zhou H, et al. IL-23R gene confers susceptibility to Behcet’s disease in a Chinese Han population. Annals of the Rheumatic Diseases. 2010;69(7):1325-1328. DOI: 10.1136/ard.2009. 119420
  11. 11. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, et al. Genome-wide association studies identify IL23R- IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nature Genetics. 2010;42:703-706. DOI: 10.1038/ ng.624
  12. 12. Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, et al. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet’s disease. Journal of Immunology. 2013;190:5799-5808. DOI: 10.4049/ jimmunol.1202677
  13. 13. Gheita TA, Gamal SM, Shaker I, El Fishawy HS, El Sisi R, Shaker OG, et al. Clinical significance of serum interleukin-23 and A/G gene (rs17375018) polymorphism in Behçets disease: Relation to neuro-Behçet, uveitis and disease activity. Joint Bone Spine. 2015;82(3):213-215. DOI: 10. 1016/j.jbspin.2014.10.008
  14. 14. Al-Okaily F, Arfin M, Al-Rashidi S, Al-Balawi M, Al-Asmari A. Inflammation-related cytokine gene polymorphisms in Behçet’s disease. Journal of Inflammation Research. 2015;8:173-180. DOI: 10.2147/JIR. S89283
  15. 15. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: A comprehensive review. Journal of Autoimmunity. 2015;64:137-148. DOI: 10.1016/j.jaut.2015. 08.013
  16. 16. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nature Genetics. 2010;42:698-702. DOI: 10.1038/ng.625
  17. 17. Gul A. Behcet’s disease: An update on the pathogenesis. Clinical and Experimental Rheumatology. 2001;19:6-12
  18. 18. Takeno M, Shimoyama Y, Kashiwakura J, Nagafuchi H, Sakane T, Suzuki N. Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behcet’s disease. Rheumatology International. 2004;24:212-216. DOI: 10.1007/s00296-003-0352-x
  19. 19. Raziuddin S, Al-Dalaan A, Bahabri S, Siraj AK, Al-Sedairy S. Divergent cytokine production profile in Behçet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol. 1998;25:329-333
  20. 20. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scandinavian Journal of Rheumatology. 2002;31:205-210
  21. 21. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis and Rheumatism. 2004;50:2291-2295. DOI: 10.1002/art.20334
  22. 22. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum Interleukin-2, Interleukin-6, tumor necrosis factor-alpha and nitric oxide levels in patients with Behcet’s disease. Annals of the Academy of Medicine, Singapore. 2004;33:596-599
  23. 23. Oztas MO, Onder M, Gurer M, Bukan AN, Sancak B. Serum interleukin 18 and tumour necrosis factor-levels are increased in Behcet’s disease. Clinical and Experimental Dermatology. 2005;30:61-63. DOI: 10.1111/ j.13 65 -2230.2004.01684.x
  24. 24. Akman A, Sallakci N, Coskun M, Bacanli A, Yavuzer U, et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet’s disease. Br J Dermatol. 2006;155(2):350-356. DOI: 10. 1111/j.1365-2133.2006.07348.x
  25. 25. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics. 1997;24:1-8
  26. 26. Sadeghi A, Davatchi F, Shahram F, Karimimoghadam A, Alikhani M, et al. Serum profiles of cytokines in Behcet’s disease. Journal of Clinical Medicine. 2017;6:49. DOI: 10.3390/ jcm6050049
  27. 27. Shimizu J, Izumi T, Arimitsu N, Fujiwara N, Ueda Y, et al. Skewed TGFβ/Smad signalling pathway in T cells in patients with Behçet’s disease. Clinical and Experimental Rheumatology. 2012;30(3 Suppl 72):S35-S39
  28. 28. Shahram F, Nikoopour E, Rezaei N, Saeedfar K, Ziaei N, et al. Association of interleukin-2, interleukin-4 and transforming growth factor-beta gene polymorphisms with Behcet’s disease. Clinical and Experimental Rheumatology. 2011;29(4 Suppl 67):S28-S31
  29. 29. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Human Immunology. 2000;61(9):863-866
  30. 30. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, et al. Cytokine gene polymorphism in human disease: On-line databases. Genes and Immunity. 1999;1(1):3-19. DOI: 10.1038/sj.gene.6363645
  31. 31. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, et al. Cytokine gene polymorphism in human disease: On-line databases, supplement 1. Genes and Immunity. 2001;2(2):61-70. DOI: 10.1038/sj.gene 636 3733
  32. 32. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine & Growth Factor Reviews. 2009;20(1):43-59. DOI: 10.1016/j.cytogfr. 2008.11.006
  33. 33. Park K, Kim N, Nam J, Bang D, Lee ES. Association of TNFA promoter region haplotype in Behcet’s disease. Journal of Korean Medical Science. 2006;21:596-601. DOI: 10.3346/jkms.2006.21.4.596
  34. 34. Liang Y, Xu WD, Zhang M, Qiu LJ, Ni J, et al. Meta-analysis of association between cytokine gene polymorphisms and Behcet’s disease risk. International Journal of Rheumatic Diseases. 2013;16:616-624. DOI: 10.1111/1756-185 X.12221
  35. 35. Zhang M, Xu WD, Wen PF, Liang Y, Liu J, et al. Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet’s disease: An updated meta-analysis. Molecular Vision. 2013;19:1913-1924
  36. 36. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, et al. TNF polymorphisms in patients with Behcet disease: A meta-analysis. Archives of Medical Research. 2010;41:142-146. DOI: 10.1016/j.arcmed. 2010. 02.002
  37. 37. Song YW, Kang EH. Behçet’s disease and genes within the major histocompatibility complex region. Modern Rheumatology. 2012;22:178-185. DOI: 10.1007/s10165-011-0542-4
  38. 38. Ates A, Kinikli G, Duzgun N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behcet’s disease. Rheumatology International. 2006;26:348-353. DOI: 10.1007/s00296-005-0610-1
  39. 39. Ben Ahmed M, Houman H, Ben Ghorbel I, Braham-Sfaxi A, Miled M, et al. Cytokine expression within mucocutaneous lesions of Behçet’s disease: Involvement of proinflammatory and Th1 cytokines. Advances in Experimental Medicine and Biology. 2003;528:343-346
  40. 40. Sharma S, Ghosh B, Sharma SK. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor(TNF)-alpha levels in Asian Indians. Clinical and Experimental Immunology. 2008;151:251-259. DOI: 10.1111/j.1365-2249.2007.03564.x
  41. 41. Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: Relevance to disease. Journal of Leukocyte Biology. 1999;66:562-566. DOI: 10.1002/jlb. 66.4.562
  42. 42. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:3195-3199. DOI: 10.1073/pnas.94.7.3195
  43. 43. Abdallah AN, Cucchi-Mouillot P, Biteau N, Cassaigne A, Haras D, Iron A. Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. European Journal of Immunogenetics. 1999;26:249-255
  44. 44. Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. Association of bladder tumors and GA genotype of −308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. Urology. 2004;64:1052-1056. DOI: 10.1016/j.urology.2004.06.018
  45. 45. Ateş O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarıkaya A. Analyses of functional IL10 and TNF-α genotypes in Behcet’s syndrome. Molecular Biology Reports. 2010;37:3637-3641. DOI: 10.1007/s11033-010-0015-4
  46. 46. Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K. Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet’s disease. Human Immunology. 2007;68:201-205. DOI: 10.1016/j.humimm.2006.12.006
  47. 47. Radouane A, Oudghiri M, Chakib A, Bennani S, Touitou I, Barat-Houari M. SNPs in the TNF-α gene promoter associated with Behcet’s disease in Moroccan patients. Rheumatology (Oxford). 2012;51:1595-1599. DOI: 10.1093/rheumatology/kes141
  48. 48. Amirzargar A, Shahram F, Nikoopour E, Rezaei N, Saeedfar K, et al. Proinflammatory cytokine gene polymorphisms in Behcet’s disease. European Cytokine Network. 2010;21:292-296. DOI: 10.1684/ecn.2009. 0209
  49. 49. Lee EB, Kim JY, Lee YJ, Park MH, Song YW. TNF and TNF receptor polymorphisms in Korean Behcet’s disease patients. Human Immunology. 2003;64:614-620
  50. 50. Chang HK, Jang WC, Park SB, Nam YH, Lee SS, et al. The novel – G646A polymorphism of the TNF-a promoter is associated with the HLA-B51 allele in Korean patients with Behcet’s disease. Scandinavian Journal of Rheumatology. 2007;36:216-221. DOI: 10.1080/03009740601154244
  51. 51. Arayssi TK, Hamdan AR, Touma Z, Shamseddeen W, Uthman IW, et al. TNF polymorphisms in Lebanese patients with Behcet’s disease. Clinical and Experimental Rheumatology. 2008;26:S130-S131
  52. 52. Duymaz-Tozkir J, Gul A, Uyar FA, Ozbek U, Saruhan-Direskeneli G. Tumor necrosis factor-alpha gene promoter region -308 and -376 G>a polymorphisms in Behcet’s disease. Clinical and Experimental Rheumatology. 2003;21:S15-S18
  53. 53. Dilek K, Ozçimen AA, Saricaoğlu H, Saba D, Yücel A, et al. Cytokine gene polymorphisms in Behçet’s disease and their association with clinical and laboratory findings. Clinical and Experimental Rheumatology. 2009;27(2 Suppl 53):S73-S78
  54. 54. Bonyadi M, Jahanafrooz Z, Esmaeili M, Kolahi S, Khabazi A, et al. TNF gene polymorphisms in Iranian Azeri Turkish patients with Behcet’s Disease. Rheumatol Int. 2009;30:285-289. DOI: 10.1007/s00296-009-1134-x
  55. 55. Alayli G, Aydin F, Coban AY, Süllü Y, Cantürk F, et al. T helper 1 type cytokines polymorphisms: Association with susceptibility to Behcet’s disease. Clinical Rheumatology. 2007;26:1299-1305. DOI: 10.1007/ s10067-006-0503-z
  56. 56. Storz K, Löffler J, Koch S, Vonthein R, Zouboulis CC, et al. IL-6 receptor, IL-8 receptor and TNF alpha 238 (G/a) polymorphisms are not associated with Behcet’s disease in patients of German or Turkish origin. Clinical and Experimental Rheumatology. 2008;26:S103-S106
  57. 57. Abdolmohammadi R, Bonyadi M. Polymorphisms of promoter region of TNF-α gene in Iranian Azeri Turkish patients with Behçet’s disease. Journal of Korean Medical Science. 2017;32(1):33-37. DOI: 10.3346/ jkms.2017.32.1.33
  58. 58. Akman A, Sallakci N, Kacaroglu H, Tosun O, Yavuzer U, et al. Relationship between periodontal findings and the TNF-alpha gene 1031T/C polymorphism in Turkish patients with Behçet’s disease. Journal of the European Academy of Dermatology and Venereology. 2008;22(8):950-957. DOI: 10.1111/j.1468-3083.2008. 02678.x
  59. 59. Lu LY, Cheng HH, Sung PK, Tai MH, et al. Tumor necrosis factor –beta +252A polymorphism is associated with systemic lupus erythematosus in Taiwan. Journal of the Formosan Medical Association. 2005;104:563-570
  60. 60. Panoulas VF, NIkas SN, Smith JP, Douglas KM, Nightingale P, et al. Lymphotoxin 252 a > G polymorphism is common associates with myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2008;67:1550-1556. DOI: 10.1136/ard.2007.082594
  61. 61. Boraska V, Zeggini E, Groves CJ, Rayner NW, Skrabić V, et al. Family-based analysis of tumor necrosis factor and lymphotoxin-alpha tag polymorphism with type 1 diabetes in the population of South Croatia. Human Immunology. 2009;70:195-199. DOI: 10.1016/j.humimm.2008.12.010
  62. 62. Al-Rayes H, Al-Swailem R, Albelawi M, Arfin M, Asmari A, Tariq M. TNF-α and TNF-β gene polymorphism in Saudi rheumatoid arthritis patients. Clin Med Insights Arthritis Musculoskelet Disord. 2011;4:55-63. DOI: 10.4137/CMAMD.S6941
  63. 63. Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, et al. Role of gamma delta T lymphocytes in the development of Behcet’s disease. Clinical and Experimental Immunology. 1997;107:241-247. DOI: 10.1111/j.1365-2249.1997.274-ce1159.x
  64. 64. Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, et al. Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet’s disease: Evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. Arthritis Research & Therapy. 2003;5:R262-R268. DOI: 10.1186/ar785
  65. 65. Messer G, Spengler U, Jung MC, Honold G, Blömer K, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: An Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. The Journal of Experimental Medicine. 1991;173:209-219. DOI: 10.1084/jem.173.1.209
  66. 66. Abraham LJ, French MAH, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor alpha. Clinical and Experimental Immunology. 1993;92:14-18. DOI: 10.1111/j.1365-2249.1993.tb059 40.x
  67. 67. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet’s disease. Tissue Antigens. 1999;54:264-272
  68. 68. Mizuki N, Inoko H, Sugmura K, Nishimura K, Nakamura S, et al. RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Behcet’s disease. Investigative Ophthalmology & Visual Science. 1992;33:3084-3090
  69. 69. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. The Journal of Allergy and Clinical Immunology. 2016;138(4):984-1010. DOI: 10.1016/j.jaci. 2016.06.033
  70. 70. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. Journal of Immunology. 1991;146:3444-3451
  71. 71. Talaat RM, Ashour ME, Bassyouni IH, Raouf AA. Polymorphisms of interleukin 6 and interleukin 10 in Egyptian people with Behcet’s disease. Immunobiology. 2014;219:573-582. DOI: 10.1016/j.imbio. 2014.03.004
  72. 72. Wallace GR, Kondeatis E, Vaughan RW, Verity DH, Chen Y, et al. IL-10 genotype analysis in patients with Behcet’s disease. Human Immunology. 2007;68:122-127. DOI: 10.1016/j.humimm.2006.11.010
  73. 73. Khaib Dit Naib O, Aribi M, Idder A, Chiali A, Sairi H, et al. Association Analysis of IL10, TNF-α, and IL23R-IL12RB2 SNPs with Behçet’s Disease Risk in Western Algeria. Front Immunol. 2013;4:342. DOI: 10.3389/fimmu.2013.00342
  74. 74. Wu Z, Zheng W, Xu J, Sun F, Chen H, et al. IL10 polymorphisms associated with Behçet’s disease in Chinese Han. Human Immunology. 2014;75:271-276. DOI: 10.1016/j.humimm.2013.11.009
  75. 75. Hu J, Hou S, Zhu X, Fang J, Zhou Y, et al. Interleukin-10 gene polymorphisms are associated with Behcet’s disease but not with Vogt-Koyanagi-Harada syndrome in the Chinese Han population. Molecular Vision. 2015;21:589-603 eCollection 2015
  76. 76. Afkari B, Babaloo Z, Dolati S, Khabazi A, Jadidi-Niaragh F, et al. Molecular analysis of interleukin-10 gene polymorphisms in patients with Behçet’s disease. Immunology Letters. 2018;194:56-61. DOI: 10.1016/j.imlet.2017.12.008
  77. 77. Montes-Cano MA, Conde-Jaldón M, García-Lozano JR, Ortiz-Fernández L, Ortego-Centeno N, et al. HLA and non-HLA genes in Behçet’s disease: A multicentric study in the Spanish population. Arthritis Research & Therapy. 2013;15(5):R145. DOI: 10.1186/ar4328
  78. 78. Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet’s disease. Arthritis Rheum. 2012;64:2761-2772. DOI: 10.1002/art.34437
  79. 79. Barış S, Akyürek Ö, Dursun A, Akyol M. The impact of the IL-1β, IL-1Ra, IL-2, IL-6 and IL-10 gene polymorphisms on the development of Behcet’s disease and their association with the phenotype. Medicina Clínica (Barcelona). 2016;146(9):379-383. DOI: 10.1016/j.medcli.2015.09.017
  80. 80. Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet’s disease. Rheumatology (Oxford). 2003;42:860-864. DOI: 10.1093/rheumatology/keg232R
  81. 81. Coskun M, Bacanli A, Sallakci N, Alpsoy E, Yavuzer U, Yegin O. Specific interleukin-1 gene polymorphisms in Turkish patients with Behcet’s disease. Exp Dermatol. 2005;14:124-129. DOI: 10.1111/j.0906-6705.2005.00253.x
  82. 82. Ozcimen AA, Dilek K, Bingöl U, Sarıcaoğlu H, Sarandöl A, et al. IL-1 cluster gene polymorphisms in Turkish patients with Behcet’s disease. International Journal of Immunogenetics. 2011;38:295-301. DOI: 10.1111/j.1744-313X.2011.01006.x
  83. 83. Katayama T, Tachinami K, Ishiguro M, Kubota Y. The relation between Behçet’s disease and interleukin-1 beta production. Nippon Ganka Gakkai Zasshi. 1994;98(2):197-201
  84. 84. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. The Journal of Clinical Investigation. 1998;102(7):1369-1376. DOI: 10.1172/JCI2629
  85. 85. Imani D, Rezaei R, Razi B, Alizadeh S, Mahmoudi M. Association between IL6-174 G/C polymorphism and Graves’ disease: A systematic review and meta-analysis. Acta Medica Iranica. 2017;55(11):665-671
  86. 86. Benešová Y, Vašků A, Bienertová-Vašků J. Association of interleukin 6, interleukin 7 receptor alpha, and interleukin 12B gene polymorphisms with multiple sclerosis. Acta Neurologica Belgica. 2018;118(3):493-501. DOI: 10.1007/s13760-018-0994-9
  87. 87. Barartabar Z, Nikzamir A, Sirati-Sabet M, Aghamohammadi E, Chaleshi V, et al. The relationship between 174 G/C and −572 G/C of IL-6 gene polymorphisms and susceptibility of celiac disease in the Iranian population. Przegla̜d Gastroenterologiczny. 2018;13(4):293-298. DOI: 10.5114/pg.2018.79808
  88. 88. Yousefi A, Najafi M, Motamed F, Mahmoudi E, Bidoki AZ, et al. Association of Interleukin-6 and Interleukin-1 family gene polymorphisms in autoimmune hepatitis. Annals of Hepatology. 2018;17(6):1021-1025. DOI: 10.5604/01.3001.0012.7202
  89. 89. Yamakawa Y, Sugita Y, Nagatani T,Takahashi S, Yamakawa T, et al. Interleukin-6 (IL-6) in patients with Behçet’s disease. Journal of Dermatological Science. 1996;11(3):189-195
  90. 90. Chang HK, Jang WC, Park SB, Han SM, Nam YH, et al. Association between interleukin 6 gene polymorphisms and Behcet’s disease in Korean people. Annals of the Rheumatic Diseases. 2005;64(2):339-340. DOI: 10.1136/ard.2004.024208
  91. 91. Xu Y, Zhou K, Yang Z, Li F, Wang Z, Xu F, et al. Association of cytokine gene polymorphisms (IL 6, IL 12B, IL 18) with Behcet’s disease: A meta-analysis. Z Rheumatol. 2016;75(9):932-938. DOI: 10.1007/s00393-015-0036-4
  92. 92. Carapito R, Shahram F, Michel S, Le Gentil M, Radosavljevic M, et al. On the genetics of the silk route: Association analysis of HLA, IL10, and IL23R-IL12RB2 regions with Behçet’s disease in an Iranian population. Immunogenetics. 2015;67(5-6):289-293. DOI: 10.1007/s00251-015-0841-6
  93. 93. Kang EH, Kim S, Park MY, Choi JY, Choi IA, et al. Behçet’s disease risk association fine-mapped on the IL23R-IL12RB2 intergenic region in Koreans. Arthritis Research & Therapy. 2017;19(1):227. DOI: 10.1186/ s13075-017-1435-5
  94. 94. Qin X, Xu J, Wu Z, Sun F, Chen H, et al. Association study of rs924080 and rs11209032 polymorphisms of IL23R-IL12RB2 in a Northern Chinese Han population with Behcet’s disease. Human Immunology. 2016;77(12):1284-1290. DOI: 10.1016/j.humimm.2016.09.006
  95. 95. Yu H, Zheng M, Zhang L, Li H, Zhu Y, et al. Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behçet’s disease in Han Chinese. The Journal of Allergy and Clinical Immunology. 2017;139(2):621-627. DOI: 10.1016/j.jaci.2016.05.024
  96. 96. Li X, Bai L, Fang J, Hou S, Zhou Q , et al. Genetic variations of IL-12B, IL-12Rβ1, IL-12Rβ2 in Behcet’s disease and VKH syndrome. PLoS One. 2014;9(5):e98373. DOI: 10.1371/journal.pone.0098373
  97. 97. Jiang Z, Hennein L, Tao Y, Tao L. Interleukin-23 receptor gene polymorphism may enhance expression of the IL-23 receptor, IL-17, TNF-α and IL-6 in Behcet’s disease. PLoS One. 2015;10(7):e0134632. DOI: 10.1371/journal.pone.0134632
  98. 98. Yalçin B, Atakan N, Dogan S. Association of interleukin-23 receptor gene polymorphism with Behçet disease. Clinical and Experimental Dermatology. 2014;39(8):881-887. DOI: 10.1111/ced.12400
  99. 99. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nature Genetics. 2013;45(2):202-207. DOI: 10.1038/ng.2520
  100. 100. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. The Journal of Clinical Investigation. 2006;116(5):1218-1222. DOI: 10.1172/JCI28508
  101. 101. Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nature Immunology. 2010;11(1):41-44. DOI: 10.1038/ni.1803
  102. 102. Chang JT, Shevach EM, Segal BM. Regulation of interleukin (IL)-12 receptor beta2 subunit expression by endogenous IL-12: A critical step in the differentiation of pathogenic autoreactive T cells. The Journal of Experimental Medicine. 1999;189(6):969-978. DOI: 10.1084/jem.189.6.969
  103. 103. Kappen JH, Medina-Gomez C, van Hagen PM, Stolk L, Estrada K, et al. Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease. PLoS One. 2015;10(3):e0119085. DOI: 10.1371/journal. Pone.0119085
  104. 104. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clinical and Experimental Immunology. 2007;149(2):217-225. DOI: 10.1111/j.1365-2249.2007.03441.x
  105. 105. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-490. DOI: 10.1016/j.immuni.2005.09.015
  106. 106. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. Journal of Immunology. 2007;179(4):2551-2555. DOI: 10.4049/jimmunol.179.4.2551
  107. 107. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008;42(3):358-364. DOI: 10.1016/j.cyto.2008.03.008
  108. 108. Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet’s disease: A review. World Journal of Gastroenterology. 2015;21(13):3801-3812. DOI: 10.3748/wjg.v21.i13.3801
  109. 109. Koca SS, Kara M, Deniz F, Ozgen M, Demir CF, Ilhan N, et al. Serum IL-33 level and IL-33 gene polymorphisms in Behçet’s disease. Rheumatology International. 2015;35(3):471-477. DOI: 10.1007/s00296-014-3111-2
  110. 110. Wahl SM, Wong H, McCartney-Francis N. Role of growth factors in inflammation and repair. Journal of Cellular Biochemistry. 1989;40(2):193-199. DOI: 10.1002/jcb.240400208
  111. 111. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988;334(6179):260-262. DOI: 10.1038/334260a0
  112. 112. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(15):6642-6646. DOI: 10.1073/pnas.88.15.6642
  113. 113. Piga M, Mathieu A. Genetic susceptibility to Behcet’s disease: Role of genes belonging to the MHC region. Rheumatology (Oxford, England). 2011;50:299-310. DOI: 10.1093/rheumatology/keq331
  114. 114. El-Menyawi M, Fawzy M, Al-Nahas Z, Edris A, Hussein H, et al. Serum tumor necrosis factor alpha (TNF-α) level in patients with Behçet’s disease: Relation to clinical manifestations and disease activity. The Egyptian Rheumatologist. 2014;36:139-143
  115. 115. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Reviews. 2006;25:409-416. DOI: 10.1007/s10555-006-9005-3
  116. 116. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. The New England Journal of Medicine. 2009;361:2033-2045. DOI: 10.1056/NEJMoa0907206
  117. 117. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, et al. Influence of –308A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis and Rheumatism. 2007;57:1426-1430. DOI: 10.1002/art.23092
  118. 118. Seitz M, Wirthmuller U, Moller B, Villiger PM. The −308 tumor necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology. 2007;46:93-96. DOI: 10.1093/rheumatology/kel175

Written By

Abdulrahman Al Asmari and Misbahul Arfin

Submitted: March 6th, 2019 Reviewed: July 27th, 2019 Published: October 2nd, 2019